Cephalon added to Nasdaq-100 Index

Cephalon Inc. said today the biopharmaceutical company in Frazer will be added to the Nasdaq-100 Index starting tomorrow.

The Nasdaq-100 Index includes 100 of the largest non-financial companies that trade on the Nasdaq stock market based on market capitalization. Cephalon's market capitalization is $5.5 billion.

"We are delighted to be recognized as part of the Nasdaq-100 Index," Cephalon's chief financial officer J. Kevin Buchi said. "Listing in the Nasdaq-100 reflects significant achievements across our business in recent years."

The company, founded in 1987, specializes in medicines for the central nervous system, pain, oncology and addiction. Cephalon sells the prescription pharmaceuticals Provigil, Fentora, Trisenox, Vivitrol, Gabitril and Actiq.

Cephalon trades on the Nasdaq under the ticker symbol CEPH. Shares were up 93 cents, or 1.13 percent, to $83.09 in midday trading.

The company has about 3,000 employees in the United States and Europe.